Amarin Corp Plc (AMRN)

[ziploc_1]

J.L. I agree. After R-IT shows a good reduction in CVD, the FDA will probably convene an Adcom panel and ask them to answer the question ..."State your level of confidence that Vascepa will lower chronic renal disease" and then the FDA will lobby the panel for a NO vote. The panel was convened to assess the success of Anchor in lowering triglycerides and then the switch was made by the FDA to a very different question for the obvious purpose of eliciting a negative vote.